Press Release

8 December 2020

Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary

Immunicum AB (publ; IMMU.ST) provided today an overview and details on the topics to be covered during the previously announced Investor Event regarding the proposed combination between Immunicum and DCprime. The live presentation and Q&A session will be led by members of the Immunicum and DCprime management teams during the webcast tomorrow, Wednesday, December 9th at 3.00 pm CET. To view the livestream of the event, click here: https://bit.ly/36V9VAQ

Questions can be sent before and during the event to ir@immunicum.com. The presentation is now available on Immunicums website.

The business combination with DCprime is a rare and exciting opportunity through which we gain improved control of the entire value chain of development for ilixadencel while adding a complementary clinical-stage program to our pipeline. This transaction is an essential step to generating shareholder value, commented Sven Rohmann, MD, Ph.D., CEO of Immunicum. Through this additional information and tomorrows Investor Event, our objective is to provide a more extensive overview of this proposed transaction to the Immunicum shareholders. Speaking for the combined leadership, we are convinced that this is a truly transformative opportunity for the Company.

Merger RationaleAs announced on November 18th, combining forces with DCprime will establish a leading company built on decades of combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology.

Building a Fully Integrated Company & Leveraging Value

Complementary Organizations & Clinical Pipeline

Broadening Shareholder Base & Financing

Transaction Process

Next Steps

Scientific BackgroundFrom a scientific perspective, both Immunicum and DCprime share the therapeutic approach of using allogeneic, off-the-shelf dendritic cell biology to enable a patients immune system to more effectively fight cancer.

Cancer Treatment in the Age of Immunotherapy

Dendritic Cells, Immunicum & DCprime

Clinical Pipeline UpdateThe combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne tumors, with two programs in Phase II clinical development and multiple near-term value inflection points as well as a portfolio of preclinical programs and research capabilities to fuel future pipeline expansion.

Combined Pipeline Overview & Upcoming Clinical Milestones

ASH Oral Presentation Update

Pipeline Expansion Opportunities

Transaction SummaryThe business combination of Immunicum and DCprime is first and foremost based on the shared and unique biology of allogeneic, off-the-shelf dendritic cell-based therapies and the complementary therapeutic approaches of intratumoral priming and cancer relapse vaccination. From this foundation, the unified company can build and expand a strong pipeline in solid and blood-borne tumors which will establish Immunicums position as a leading cell therapy player. This pipeline will also facilitate near- and long-term clinical development progress and value creation.

In addition, as two synergistic organizations, Immunicum and DCprime will bring together and further develop strong in-house research and process development capabilities.

Van Herk and AP4, two leading institutional investors, have expressed their support to the combined entity.

For more information, please contact:

Sven Rohmann, MD, Ph.D., CEOTelephone: +46 8 732 8400E-mail: info@immunicum.com

Investor Relations

Jonas Rodny and Carolin WikenPaues berg CommunicationsTelephone: +46 190 90 51 E-mail:ir@immunicum.com

Media Relations

Joanne Tudorica and Sophia Hergenhan, Ph.D.Trophic CommunicationsTelephone: +49 171 351 2733E-mail:ir@immunicum.com

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patients own immune system to fight cancer. The Companys lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. http://www.immunicum.com

Read the rest here:
Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary - GlobeNewswire